Blueberry compound may boost cancer treatment in small trial
NCT ID NCT03671811
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding pterostilbene, an antioxidant found in blueberries, to the hormone drug megestrol acetate can better slow endometrial cancer growth before hysterectomy. About 44 patients will receive either megestrol acetate alone or with pterostilbene for a short time before surgery. The main goal is to see if the combination reduces tumor cell growth more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- megestrol acetate and pterostilbene
- What this could lead to
- If it works, this could point toward a way to shrink endometrial tumors before surgery, possibly improving outcomes.
- What could go wrong
- This is a small, early-phase trial with only 44 participants, so results may not apply widely. The added benefit of pterostilbene is uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL ENDOMETRIAL HYPERPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a natural compound boost chemotherapy against endometrial cancer?
- Can a new nucleotide analogue boost cancer treatment?
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Could a common Weight-Loss drug help hormone therapy work better for young women with endometrial cancer?
- Could a lighter immunotherapy schedule keep advanced cancers in check?